SI1855674T1 - Sestavek za inhibicijo katepsina k - Google Patents

Sestavek za inhibicijo katepsina k

Info

Publication number
SI1855674T1
SI1855674T1 SI200631814T SI200631814T SI1855674T1 SI 1855674 T1 SI1855674 T1 SI 1855674T1 SI 200631814 T SI200631814 T SI 200631814T SI 200631814 T SI200631814 T SI 200631814T SI 1855674 T1 SI1855674 T1 SI 1855674T1
Authority
SI
Slovenia
Prior art keywords
cathepsin
inhibition
composition
Prior art date
Application number
SI200631814T
Other languages
English (en)
Inventor
Anastasia Daifotis
Selwyn Aubrey Stoch
Basil Avery Ince
Cameron Black
Original Assignee
Merck Sharp & Dohme Corp.
Merck Canada Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37962942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1855674(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme Corp., Merck Canada Inc. filed Critical Merck Sharp & Dohme Corp.
Publication of SI1855674T1 publication Critical patent/SI1855674T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5929,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/26Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SI200631814T 2005-03-02 2006-02-24 Sestavek za inhibicijo katepsina k SI1855674T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65798205P 2005-03-02 2005-03-02
EP06844077.5A EP1855674B1 (en) 2005-03-02 2006-02-24 Composition for inhibition of cathepsin k
PCT/US2006/006622 WO2007046842A2 (en) 2005-03-02 2006-02-24 Composition for inhibition of cathepsin k

Publications (1)

Publication Number Publication Date
SI1855674T1 true SI1855674T1 (sl) 2014-10-30

Family

ID=37962942

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200631814T SI1855674T1 (sl) 2005-03-02 2006-02-24 Sestavek za inhibicijo katepsina k

Country Status (12)

Country Link
US (3) US8722734B2 (sl)
EP (2) EP1855674B1 (sl)
JP (4) JP2008531691A (sl)
CN (2) CN101128200A (sl)
AU (1) AU2006302797B2 (sl)
CA (1) CA2599572A1 (sl)
DK (1) DK1855674T3 (sl)
ES (1) ES2510494T3 (sl)
PL (1) PL1855674T3 (sl)
PT (1) PT1855674E (sl)
SI (1) SI1855674T1 (sl)
WO (1) WO2007046842A2 (sl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR055283A1 (es) * 2004-11-23 2007-08-15 Merck Frosst Canada Ltd Inhibidores de cisteinproteasa de catepsina
US20090318560A1 (en) * 2007-02-26 2009-12-24 Wayne Parent Formulations for cathepsin k inhibitors
WO2009140105A2 (en) 2008-05-14 2009-11-19 Merck & Co., Inc. Formulations for cathepsin k inhibitors
CN103381152A (zh) * 2013-02-05 2013-11-06 吉林省金梓源生物科技有限公司 杨梅素作为组织蛋白酶k抑制剂的用途
EP3019468A4 (en) * 2013-07-11 2017-01-11 Merck Sharp & Dohme Corp. Formulations for cathepsin k inhibitors with vitamin d
WO2015051479A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
CN112912367A (zh) * 2018-08-02 2021-06-04 英特维特国际股份有限公司 N1-(1-氰基环丙基)-n2-((1s)-1-{4′-[(1r-2,2-二氟-1-羟基乙基]联苯基-4-基}-2,2,2-三氟乙基)-4-氟-l-亮氨酸酰胺的结晶形式
JP7431419B2 (ja) * 2018-11-14 2024-02-15 タイワン リポソーム カンパニー リミテッド 骨密度の低下または軟骨損失による疾患を治療するための治療剤を含む徐放性医薬組成物およびその使用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA777769A (en) 1963-03-18 1968-02-06 H. Roy Clarence Substituted methylene diphosphonic acid compounds and detergent compositions
US4330537A (en) * 1977-12-07 1982-05-18 The Procter & Gamble Company Compositions for inhibiting mobilization of calcium phosphate in animal tissue
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4319039A (en) 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
US4294926A (en) 1979-06-15 1981-10-13 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
JPS5889191A (ja) 1981-11-20 1983-05-27 Sankyo Co Ltd 3−ヒドロキシ−ml−236b誘導体の製造法
JPS591415A (ja) * 1982-06-28 1984-01-06 Mochida Pharmaceut Co Ltd 循環系疾患治療剤
FR2531088B1 (fr) 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
HU204253B (en) 1982-11-22 1991-12-30 Sandoz Ag Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4911165A (en) 1983-01-12 1990-03-27 Ethicon, Inc. Pliabilized polypropylene surgical filaments
US4761406A (en) 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4885314A (en) 1987-06-29 1989-12-05 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4782084A (en) 1987-06-29 1988-11-01 Merck & Co., Inc. HMG-COA reductase inhibitors
US4820850A (en) 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
CA1339805C (en) 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
US5180589A (en) 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US5030447A (en) 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US4916239A (en) 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
US5118853A (en) 1988-10-13 1992-06-02 Sandoz Ltd. Processes for the synthesis of 3-disubstituted aminoacroleins
US5290946A (en) 1988-10-13 1994-03-01 Sandoz Ltd. Processes for the synthesis of 3-(substituted indolyl-2-yl)propenaldehydes
US4929437A (en) 1989-02-02 1990-05-29 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
US5189164A (en) 1989-05-22 1993-02-23 Sandoz Ltd. Processes for the synthesis of syn-(E)-3,5-dihydroxy-7-substituted hept-6-enoic and heptanoic acids and derivatives and intermediates thereof
US4922007A (en) 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5019651A (en) 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
HU217629B (hu) 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
TW257765B (sl) 1993-08-25 1995-09-21 Merck & Co Inc
US5510517A (en) 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
WO1998001133A1 (fr) * 1996-07-08 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Inhibiteurs de la resorption osseuse
EP1088333A4 (en) * 1998-06-24 2005-08-10 Merck & Co Inc METHOD AND COMPOSITIONS FOR CONNECTING OSTEOPROSIS
ATE524170T1 (de) 2000-02-14 2011-09-15 Merck Sharp & Dohme Östrogenrezeptor modulatoren
JP4119246B2 (ja) 2000-11-27 2008-07-16 メルク エンド カムパニー インコーポレーテッド エストロゲンレセプター修飾物質
EP1446114A4 (en) 2001-11-08 2005-05-25 Merck & Co Inc COMPOSITIONS AND METHODS FOR TREATING OSTEOPOROSIS
JP2005516928A (ja) * 2001-12-13 2005-06-09 メルク エンド カムパニー インコーポレーテッド 骨異常のためのビスホスホネート液体製剤
US7375134B2 (en) 2002-03-05 2008-05-20 Axys Pharmaceuticals, Inc. Cathepsin cysteine protease inhibitors
JP2004256525A (ja) * 2003-02-06 2004-09-16 Sankyo Co Ltd N−[1−置換−2−(アリールアミノ)エチル]アミド誘導体
US7405229B2 (en) 2003-06-30 2008-07-29 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
AU2004296905A1 (en) * 2003-12-12 2005-06-23 Merck Frosst Canada Ltd Cathepsin cysteine protease inhibitors
AR055283A1 (es) * 2004-11-23 2007-08-15 Merck Frosst Canada Ltd Inhibidores de cisteinproteasa de catepsina
WO2006076797A1 (en) * 2005-01-19 2006-07-27 Merck Frosst Canada Ltd. Cathepsin k inhibitors and atherosclerosis
ATE553090T1 (de) * 2005-07-06 2012-04-15 Merck Canada Inc Cathepsincysteinproteasehemmer

Also Published As

Publication number Publication date
EP1855674A4 (en) 2011-05-25
AU2006302797B2 (en) 2012-02-02
JP2013227327A (ja) 2013-11-07
CA2599572A1 (en) 2007-04-26
PL1855674T3 (pl) 2015-01-30
JP2015227349A (ja) 2015-12-17
EP1855674A2 (en) 2007-11-21
US8722734B2 (en) 2014-05-13
WO2007046842A3 (en) 2007-07-12
DK1855674T3 (da) 2014-10-20
EP1855674B1 (en) 2014-07-16
CN104188952A (zh) 2014-12-10
EP2783687A1 (en) 2014-10-01
US20080255072A1 (en) 2008-10-16
US20140186471A1 (en) 2014-07-03
WO2007046842A2 (en) 2007-04-26
JP2017095512A (ja) 2017-06-01
PT1855674E (pt) 2014-10-08
JP2008531691A (ja) 2008-08-14
AU2006302797A1 (en) 2007-04-26
US20150250759A1 (en) 2015-09-10
JP6159170B2 (ja) 2017-07-05
CN101128200A (zh) 2008-02-20
ES2510494T3 (es) 2014-10-21

Similar Documents

Publication Publication Date Title
ZA200705783B (en) Amino-imidazolones for the inhibition of ß-secretase
GB2426023B (en) Structured composite compositions for treatment of subterranenan wells
ZA200706345B (en) Amino-pyridines as inhibitors of ß-secretase
IL189933A0 (en) Rna antagonist compounds for the inhibition of apo-b100 expression
PL2335782T3 (pl) Zastosowanie kompozycji zawierającej HFCO-1233zd
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en) PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
IL190753A0 (en) Compositions of lipoxygenase inhibitors
EP1871331A4 (en) COMPOSITION FOR THE TREATMENT OF MENOPAUSE
SG137989A1 (en) Compositions and methods for inhibition of the JAK pathway
EP1996612A4 (en) COMPOSITIONS FOR THE TREATMENT OF CANCER
ZA200806185B (en) Antiperspirant compositions
EP1891924A4 (en) COMPOSITION FOR PROTECTING THE SURFACE OF A BODY
IL184569A0 (en) Intravenous formulations of pde-5 inhibitors
EP1863473A4 (en) NEW USE OF LIGNAN CONNECTIONS
EP1973557A4 (en) NON-HYGROSCOPIC COMPOSITIONS OF ENTEROSTATIN
PL1855674T3 (pl) Kompozycja do hamowania katepsyny K
EP1908459A4 (en) COMPOSITION PREVENTING CANCER
IL188850A0 (en) Cathepsin k inhibitors
EP2132173A4 (en) FORMULATIONS FOR CATHEPSIN K-HEMMER
IL186606A0 (en) Compositions and uses of amooranin compounds
GB0618703D0 (en) Synthesis of leikotriene compounds
GB0412584D0 (en) Composition of matter
EP1744755A4 (en) COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S HEMMER
IL185136A0 (en) Oral compositions for the prevention of uv damages